Stockreport

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics, Inc.  (ATXS) 
PDF -- Navenibart (STAR-0215), the Potential Market-Leading Therapy for the Treatment of Hereditary Angioedema, on Track for Expected Phase 3 Initiation in Q1 2025 ---- Fina [Read more]